Zacks Investment Research on MSN

Masimo SET shows accurate pulse oximetry in newborns of all skin tones

Masimo MASI recently reported findings from the NeoPODS study, a large prospective real-world evaluation of its SET pulse oximetry technology in critically ill newborns. The study demonstrated less ...
The Daily Reflector

Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study

Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET ® pulse oximetry among ...
FierceBiotech

FDA clears Masimo's over-the-counter Stork baby monitoring system

Masimo secured FDA clearance for its Stork baby monitoring system that can help track certain vital signs in healthy infants up to 18 months old and provide alarms to parents or caregivers. The newly ...
CNET

FDA Clears Masimo's 'Stork' Baby Monitor for Blood Oxygen, Pulse Rate Monitoring

Masimo, the health technology company that made headlines last winter over a dispute with Apple and its blood oxygen sensing technology, said Monday that its wearable Stork baby monitor is now cleared ...
FierceBiotech

Masimo paints pulse oximetry tech onto GE HealthCare's Portrait patient monitoring system

More than a decade into their partnership, Masimo and GE HealthCare are still finding new ways to combine their respective patient monitoring technologies. In the latest expansion of their ...
Business Wire

Masimo Receives FDA Clearance for Stork™ Baby Monitoring System

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a global leader in innovative monitoring technologies used in top hospitals, announced today FDA clearance of Stork™, a revolutionary baby ...